Free Trial

Vanguard Group Inc. Has $771.67 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories logo with Medical background

Vanguard Group Inc. increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,389,889 shares of the medical research company's stock after purchasing an additional 46,119 shares during the quarter. Vanguard Group Inc. owned approximately 8.38% of Bio-Rad Laboratories worth $771,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Wahed Invest LLC purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $113,000. Wellington Management Group LLP purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $2,543,000. Goldman Sachs Group Inc. grew its stake in Bio-Rad Laboratories by 454.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 144,333 shares of the medical research company's stock valued at $46,604,000 after acquiring an additional 118,304 shares in the last quarter. Virtu Financial LLC purchased a new position in Bio-Rad Laboratories during the 4th quarter valued at about $330,000. Finally, Winslow Asset Management Inc. grew its stake in Bio-Rad Laboratories by 2.9% during the 4th quarter. Winslow Asset Management Inc. now owns 22,056 shares of the medical research company's stock valued at $7,122,000 after acquiring an additional 613 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Insider Buying and Selling

In related news, EVP Michael Crowley sold 369 shares of the business's stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the sale, the executive vice president now directly owns 6,573 shares in the company, valued at approximately $1,852,994.43. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 17.06% of the company's stock.


Analysts Set New Price Targets

Several research firms have weighed in on BIO. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Tuesday, May 28th. UBS Group lowered their target price on Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating on the stock in a research note on Wednesday, May 8th. Jefferies Financial Group reiterated a "hold" rating and set a $315.00 price target (down from $440.00) on shares of Bio-Rad Laboratories in a report on Monday, June 3rd. Finally, Citigroup lowered Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and reduced their price target for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $436.67.

View Our Latest Stock Report on BIO

Bio-Rad Laboratories Stock Up 0.8 %

Shares of Bio-Rad Laboratories stock traded up $2.36 during trading on Friday, hitting $287.98. 1,318,032 shares of the stock traded hands, compared to its average volume of 220,632. The stock has a market cap of $8.21 billion, a P/E ratio of -27.80 and a beta of 0.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $431.79. The company has a fifty day moving average price of $285.18 and a two-hundred day moving average price of $311.47.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The firm had revenue of $610.82 million during the quarter, compared to analyst estimates of $619.09 million. During the same period in the previous year, the company earned $3.34 EPS. The company's revenue for the quarter was down 9.8% on a year-over-year basis. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.8 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

See Also

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

→ AI’s Biggest Problem (From Weiss Ratings) (Ad)

Should you invest $1,000 in Bio-Rad Laboratories right now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Opportunities Arise as Stock Market Rotates from Big Tech

Opportunities Arise as Stock Market Rotates from Big Tech

Discover how the great stock rotation is shaking up the market and what it means for your investments, including the companies poised for growth.

Related Videos

3 Top Market Leaders Splitting Their Stocks
CPI News Breakdown: Key Market Moves to Follow
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines